What is the P-tau217 blood test?

A blood test that detects P-tau217 protein, a biomarker for Alzheimer's, aiding early diagnosis.

What is Eli Lilly's stock ticker?

LLY, traded on the New York Stock Exchange (NYSE).

Is Kisunla currently available?

Yes, by prescription in the United States.

Eli Lilly to Present New Alzheimer's Data at AAIC 2026

Q: When will Eli Lilly present this data?

At the 2026 Alzheimer's Association International Conference (AAIC).

Eli Lilly announces plans to present new Alzheimer's research at AAIC 2026, including long-term Kisunla data and blood-based diagnostic updates.

July 11, 2026

2 min read

Source: Simply Wall St.

Eli Lilly (NYSE:LLY) intends to showcase its latest Alzheimer's research at the 2026 Alzheimer's Association International Conference (AAIC), including long-term data on Kisunla (donanemab-azbt). The company will also provide updates on the drug's safety and biomarker findings, along with progress on a blood-based P-tau217 diagnostic test aimed at broader Alzheimer's screening.

The Product

Kisunla is an amyloid-targeting immunotherapy approved by the FDA for early-stage Alzheimer's disease. The new data aims to demonstrate long-term efficacy.

Pricing and Availability

No pricing or availability changes were announced. Kisunla is currently available by prescription in the U.S.

Competition

Kisunla competes with similar drugs like Leqembi (Eisai/Biogen). The P-tau217 blood test could provide a competitive edge by enabling earlier diagnosis.

Potential Impact on the Company

Positive long-term data could boost investor confidence in Kisunla, while the blood test may expand the eligible patient population.

Frequently Asked Questions

Kisunla is an amyloid-targeting immunotherapy approved by the FDA for early Alzheimer's disease.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.